BioCentury
ARTICLE | Clinical News

BKT-140: Phase IIa started

April 15, 2013 7:00 AM UTC

This quarter, BioLineRx will begin an open-label, dose-escalation, U.S. and Israeli Phase IIa trial to evaluate BL-8040 in up to 50 adults with relapsed or refractory AML. Biokine granted BioLineRx ex...